IMA ImageneBio Inc
USHealthcareAs of 2026-07-10 16:00
Why IMA matters now
ImageneBio Inc (IMA) is a US stock in Healthcare. The latest InvestLog snapshot shows $5.91 with +0.17% on the session and $66.7M in market capitalization; recent performance reads 1-month +14.29% and YTD -13.04%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-10.6M, and EPS of $-0.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -77.0%.
The latest indexable market news headline is "ImageneBio Appoints Matt Robbins as General Counsel" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $1.33; recent insider activity includes Bonita David P filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.55
P/S
0.00
EV/EBITDA
0.00
DCF Value
$4.99
FCF Yield
-77.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-35.2%
ROA
-33.0%
ROIC
-42.0%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-10.6M | $-0.95 |
| Q4 2025 | $0.00 | $-6.9M | $-0.62 |
| FY 2025 | $800.0K | $-45.3M | $-10.76 |
| Q3 2025 | $0.00 | $-24.8M | $-3.01 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$1.33
Target (Median)
$1.33
Target Range
$1.33 - $1.33
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.72
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.